- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has backed using AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 drug treatment.
- AstraZeneca said the EMA had backed Evusheld as a treatment for adults and adolescents with COVID who do not need supplemental oxygen and are at increased risk of worsening their disease.
- The antibody cocktail was previously only approved as a preventative treatment for people with compromised immune systems who see little or no benefit from vaccines.
- Related: AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment.
- The EMA also endorsed Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
- Related: AstraZeneca-Sanofi’s Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants.
- AstraZeneca is developing Beyfortus along with Sanofi SA (NASDAQ:SNY).
- The pharma giant also said that if Beyfortus is approved, it will become the first protective option for newborn and infant population against RSV lower respiratory tract disease.
- Price Action: AZN shares are up 1.82% at $59.20 during the premarket session on the last check Friday.
Verona Pharma Stock Garners Investors’ Attention After Successful COPD Trial
Verona Pharma plc (NASDAQ:VRNA) has announced positive results of its Phase 3 ENHANCE-1 trial of nebulized ensifentrine for the maintenance treatment…
